Results 21 to 30 of about 39,881 (211)

Extended thromboprophylaxis with betrixaban in acutely ill medical patients [PDF]

, 2016
BACKGROUND: Patients with acute medical illnesses are at prolonged risk for venous thrombosis. However, the appropriate duration of thromboprophylaxis remains unknown.
. Lodigiani, M, : W. Ageno, I, Cerveri, A., Cohen, Alexander T, De Pellegrin, D, D’Angelo, A, Gibson, C. Michael, Gold, Alex, Goldhaber, Samuel Z., Harrington, Robert A., Hernandez, Adrian F., Hull, Russell D., Imberti, R., Investigators, Italy (261 patients, 19 sites, Landolfi, G, LEMBO, Giuseppe, Luisetti, M., Wiens, Brian L.   +18 more
core   +1 more source

Characterizing the delays in adequate thromboprophylaxis after TBI

Trauma Surgery & Acute Care Open, 2021
Background We sought to compare enoxaparin dosing for venous thromboembolism (VTE) prophylaxis in trauma patients with and without traumatic brain injury (TBI) to better understand the time and dose required to reach target anti-Xa levels. Our hypothesis
Eric J Ley, Navpreet K Dhillon, Yassar M Hashim, Naomi Berezin, Felix Yong, Geena Conde, Russell Mason   +6 more
doaj   +1 more source

Efficacy, Safety, and Timing of Anticoagulant Thromboprophylaxis for the Prevention of Venous Thromboembolism in Patients With Acute Spinal Cord Injury: A Systematic Review [PDF]

, 2017
Study Design: Systematic review. Objectives: The objective of this study was to answer 5 key questions: What is the comparative effectiveness and safety of (1a) anticoagulant thromboprophylaxis compared to no prophylaxis, placebo, or another ...
Arnold, Paul M., Casha, Steve, Fehlings, Michael G., Harrop, James S., Holmer, Haley K., Kwon, Brain K., Merli, Geno J., Norvell, Daniel C., Palmieri, Katherine, Tetreault, Lindsay G., Wilson, Jefferson R.   +10 more
core   +2 more sources

Critically ill patients with edema and ascites may experience subtherapeutic anti-factor Xa levels following abdominal subcutaneous enoxaparin treatment

SAGE Open Medical Case Reports, 2022
Enoxaparin is a low molecular weight heparin that is principally prescribed for the treatment and prevention of thromboembolic disorders. In clinical practice, the abdominal site for subcutaneous enoxaparin administration is most preferable because of ...
Vichapat Tharanon, Theerasuk Kawamatawong   +1 more
doaj   +1 more source

Edoxaban: an update on the new oral direct factor Xa inhibitor. [PDF]

, 2014
Edoxaban is a once-daily oral anticoagulant that rapidly and selectively inhibits factor Xa in a concentration-dependent manner. This review describes the extensive clinical development program of edoxaban, including phase III studies in patients with ...
A. John Camm, AC Skanes, AG Turpie, AJ Camm, AK Kakkar, AT Cohen, B Laulicht, BF Gage, BI Eriksson, BI Eriksson, BI Eriksson, BI Eriksson, BS Stambler, C Kearon, CB Granger, CT Ruff, DE Salazar, G Agnelli, G Agnelli, G Lu, G Raskob, G Raskob, H Masumoto, H Zahir, Henri Bounameaux, J Mendell, J Mendell, J Mendell, J Mendell, J Mendell, J Mendell, J Stampfuss, JH Alexander, JI Weitz, JL Mega, K Ogata, KL Furie, LT Grip, M Crowther, M Hori, M Pirmohamed, MR Lassen, MR Lassen, MR Lassen, MR Lassen, MR Patel, MS Bathala, MU Zafar, N Chung, N Matsushima, R Caterina De, R Caterina De, RP Giugliano, S Kaatz, S Schulman, S Schulman, S Schulman, SE Kimmel, SJ Connolly, SJ Connolly, SJ Connolly, SZ Goldhaber, T Fuji, T Fuji, T Fukuda, T Hulle van der, T Mikkaichi, T Wilke, T Yamashita, TI Verhoef, W Mueck, Y Falck-Ytter, Y Kuroda   +72 more
core   +1 more source

Cancer and thrombosis: Managing the risks and approaches to thromboprophylaxis [PDF]

, 2006
Patients with cancer are at increased risk of venous thromboembolism (VTE) compared with patients without cancer. This results from both the prothrombotic effects of the cancer itself and iatrogenic factors, such as chemotherapy, radiotherapy, indwelling
Altinbas M, Athanasoulis CA, Bergqvist D, Bergqvist D, Buller HR, Clagett PG, Da Silva MS, Decousus H, ENOXACAN Study Group, Falanga A, Geerts WH, Gitter MJ, Goldenberg N, Gomes MPV, Green D, Haas S, Heit JA, Hettiarachchi RJK, Hull R, Hutten BA, International Multicentre Trial, Johnson MJ, Kakkar VV, Karthaus M, Koopman MMW, Levine MN, Mousa S A, Mousa SA, Prandoni P, Rasmussen MS, Rickles FR, Sallah S, Samama M, Siragusa B, The Columbus Investigators, White RH, Zacharski LR   +36 more
core   +1 more source

Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period [PDF]

, 2010
Some women are at risk of forming blood clots in a deep vein during pregnancy, after a caesarean birth, or during the first few weeks after childbirth. If part of the clot breaks off and lodges in a blood vessel in the lungs, it can be life-threatening ...
Abou-Nassar, Abou-Nassar, Alfirevic, Alikhan, Andersen, Atrash, Badawy, Barbour, Bates, Blomback, Brenner, Brenner, Brenner, Brenner, Brenner, Brenner, Brill-Edwards, Brocklehurst, Brocklehurst, Brocklehurst, Burrows, Casele, Casele, Chistolini, Cohen, Conard, Connolly, Cornette, Dargaud, Dendrinos, Dittmer, Ellison, Ellison, Ellison, Empson, Farquharson, Friederich, Gates, Gates, Gates, Gherman, Gibson, Hall, Hamersley, Harenberg, Heilman, Heilmann, Heit, Hill, Hill, Howell, Högberg, Kaandorp, Kakkos, Kamin, Knight, Krauss, Kutteh, Kutteh, Larciprete, Letsky, Lewis, Lindhagen, Lindqvist, Macklon, Middeldorp, Nelson-Piercy, Noble, Orme, Paull, Pettila, Pettila, Pomp, Rai, Ramos, Rey, Rey, Rodger, Rodger, Rodger, Rutherford, Segal, Simpson, Stefano, Stephenson, Taylor, Testroote, Thaler, Tulppala, Veciana, Walker, Welti, Wu   +92 more
core   +1 more source

Dosis Efektif Enoxaparin dalam Mencegah Terjadinya Trombosis pada Anastomosis Arteri Femoralis Tikus

JBN (Jurnal Bedah Nasional), 2017
Tujuan: untuk mengetahui dosis efektif enoxaparin dalam mencegah terjadinya trombosis pada anastomosis mikrovaskular. Metode: penelitian ini bersifat eksperimental dengan rancangan the randomized post test only control group design.
I Made Suka Adnyana, Iswinarno Doso Saputro   +1 more
doaj   +1 more source

Enoxaparin-induced reactive thrombocytosis: a case report

Thrombosis Journal, 2021
Background Enoxaparin is an anticoagulant that falls in the class of medications called low molecular weight heparins (LMWHs), and is used to prevent or treat patients with deep vein thrombosis (DVT) and pulmonary embolism.
Tao Xiang, Ming Cheng
doaj   +1 more source

Dose-dependent neuroprotective effect of enoxaparin on cold-induced traumatic brain injury

Neural Regeneration Research, 2017
Recent evidence exists that enoxaparin can reduce brain injury because of its anticoagulant activity. To investigate the potential therapeutic effect of enoxaparin on cold-induced traumatic brain injury, at 20 minutes after modeling, male BALB/c mouse ...
Ilknur Keskin, M Yalcin Gunal, Nilufer Ayturk, Ulkan Kilic, Mehmet Ozansoy, Ertugrul Kilic   +5 more
doaj   +1 more source